Cover Image
市場調查報告書

PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 日本的醫藥品市場到2023年前的預測與市場分析

PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325948
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 日本的醫藥品市場到2023年前的預測與市場分析 PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 200 Pages
簡介

黃斑部水腫(ME)是液體積存黃斑的狀態,會引起視力障礙,甚至嚴重到造成失明。老年性黃斑部病變(AMD)是沒有痛覺的眼睛疾病,造成階段性,不可逆的視力低落,是五十歲以上,已開發國家人民的主要失明原因之一。

本報告提供日本的黃斑部水腫 (ME) 和黃斑部病變 (MD) 的治療藥市場相關調查分析,提供您疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 黃斑部病變 (MD) 概要
  • 黃斑部水腫 (ME) 概要

第4章 疾病的管理

  • 診斷和治療概要
  • 日本

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌

第6章 未滿足需求和機會

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 初期開發中的有潛力的藥劑
  • 其他開發中的藥物
  • 生技仿製藥

第8章 市場預測

  • 日本

第9章 附錄

圖表

目錄
Product Code: GDHC263CFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Japan has an increasingly aging society, which will act as a significant driver of growth in this market, along with the introduction of novel therapies for both wet and dry AMD. The wAMD drugs, Fovista and abicipar pegol, are expected to enter the Japanese AMD market in 2019 and 2023, respectively, while the dAMD drugs, lampalizumab and emixustat, are both expected to enter in 2018.

Scope

  • Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Macular Edema and Macular Degeneration market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Lucentis (ranibizumab)
    • 5.2.2. Eylea (aflibercept)
    • 5.2.3. Avastin (bevacizumab)
    • 5.2.4. Macugen (pegaptanib sodium)
    • 5.2.5. Visudyne (verteporfin)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment for Dry AMD
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Longer-Acting Anti-VEGF Drug Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Less Invasive Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Awareness and Earlier Patient Diagnosis
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Home Monitoring of AMD Progression
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Abicipar pegol
    • 7.2.2. Fovista
    • 7.2.3. Lampalizumab
    • 7.2.4. Emixustat
    • 7.2.5. DE-102
  • 7.3. Promising Drugs in Early-Stage Development
    • 7.3.1. Complement Inhibitors
  • 7.4. Other Drugs in Development
  • 7.5. Biosimilars

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Japan - Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed ME and AMD Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-Prescribers Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Japan Market, 2013
  • Table 5: ME and AMD Disease Management - Japan
  • Table 6: Leading Treatments for ME and AMD, 2014
  • Table 7: Product Profile - Lucentis
  • Table 8: Lucentis SWOT Analysis, 2014
  • Table 9: Approval Dates for Eylea
  • Table 10: Product Profile - Eylea
  • Table 11: Eylea - Common Adverse Reactions
  • Table 12: Eylea SWOT Analysis, 2014
  • Table 13: Product Profile - Avastin
  • Table 14: Avastin SWOT Analysis, 2014
  • Table 15: Product Profile - Macugen
  • Table 16: Product Profile - Visudyne
  • Table 17: Visudyne SWOT Analysis, 2014
  • Table 18: Unmet Needs and Opportunities in ME and AMD
  • Table 19: Promising Drugs in Clinical Development for ME and AMD
  • Table 20: Comparison of Drugs in Development for ME and AMD, 2014
  • Table 21: Product Profile - Abicipar pegol
  • Table 22: SWOT Analysis - Abicipar pegol, 2014
  • Table 23: Product Profile - Fovista
  • Table 24: SWOT Analysis - Fovista, 2014
  • Table 25: Product Profile - Lampalizumab
  • Table 26: SWOT Analysis - Lampalizumab, 2014
  • Table 27: Product Profile - Emixustat
  • Table 28: SWOT Analysis - Emixustat, 2014
  • Table 29: Product Profile - DE-102
  • Table 30: DE-102 SWOT Analysis, 2014
  • Table 31: Early-Stage Drugs in Clinical Development for ME and AMD, 2014
  • Table 32: Sales Forecast ($m) for ME in Japan, 2013-2023
  • Table 33: Sales Forecast ($m) for AMD in Japan, 2013-2023
  • Table 34: Key Events Impacting Sales for ME and AMD in Japan, 2013-2023
  • Table 35: ME and AMD Markets - Drivers and Barriers, 2013-2023
  • Table 36: ME and AMD Markets - Drivers and Barriers in Japan, 2013-2023
  • Table 37: Key Launch Dates
  • Table 38: Key Patent Expiries
  • Table 39: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Eylea's Clinical Development in DME and ME-BRVO
  • Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
  • Figure 13: Abicipar Pegol's Clinical Development in wAMD and DME
  • Figure 14: Clinical and Commercial Positioning of abicipar pegol
  • Figure 15: Fovista's Clinical Development in wAMD
  • Figure 16: Clinical and Commercial Positioning of Fovista
  • Figure 17: Lampalizumab's Development in wAMD
  • Figure 18: Clinical and Commercial Positioning of lampalizumab
  • Figure 19: Emixustat Clinical Development in dAMD
  • Figure 20: Clinical and Commercial Positioning of emixustat
  • Figure 21: DE-102's Clinical Development in DME and ME-BRVO
  • Figure 22: Clinical and Commercial Positioning of DE-102
  • Figure 23: Individual Drug Sales for ME in Japan, 2013-2023
  • Figure 24: Individual Drug Sales for AMD in Japan, 2013-2023
Back to Top